Top 5 Performing Stocks For 2014

The following video is from Wednesday’s Investor Beat, in which host Chris Hill, and analysts Jason Moser and Matt Argersinger, dissect the hardest-hitting investing stories of the day.

Yahoo’s (NASDAQ: YHOO  )  second-quarter earnings rose 46%, but the company missed on revenue, as advertising took a hit. Despite the expectations miss, the stock continues to rally. In this video, Matt and Jason discuss why CEO Marissa Mayer continues to drive so much investor confidence, and what we can expect from her and the company as she enters her second year as Yahoo’s first in command.

It’s incredible to think just how much of our digital and technological lives are almost entirely shaped and molded by just a handful of companies. Find out “Who Will Win the War Between the 5 Biggest Tech Stocks?” in The Motley Fool’s latest free report, which details the knock-down, drag-out battle being waged by the five kings of tech. Click here to keep reading.

Top 5 Performing Stocks For 2014: Pacific Ethanol Inc.(PEIX)

Pacific Ethanol, Inc. produces and markets low carbon renewable fuels in the United States. It sells ethanol to gasoline refining and distribution companies; provides ethanol transportation, storage, and delivery services in the Western United States, primarily in California, Arizona, Nevada, Utah, Oregon, Colorado, Idaho, and Washington; and markets ethanol co-products, including wet distiller grains and syrup to dairy operators and animal feed distributors. The company also provides operations, maintenance, and accounting services to a cellulosic integrated bio-refinery in Boardman, Oregon. Pacific Ethanol, Inc. was founded in 2003 and is headquartered in Sacramento, California.

Advisors’ Opinion:

  • [By James E. Brumley]

    Have you ever noticed how the worst time to get into a stock is when the buzz is the loudest, while the best time to sneak into a stock is when nobody’s talking about it? Yeah, well, you can add Pacific Ethanol Inc. (NASDAQ:PEIX) to the list of names that’s pretty much fooled everyone, then, and now. PEIX was all the rage five years ago, and ended up getting trashed between 2007 and 2008. Despite repeated attempts to get, multiple headaches for the ethanol industry just never let the stock pick itself up. Now, a full year after anybody stopped caring about the stock (bearishly or bullishly), and Pacific Ethanol has quietly doled out a huge 200% gain since November.

  • [By Paul Ausick]

    Ethanol producers and farmers are the losers and the RFA is steaming mad. The group claims that the “EPA is proposing to place the nation’s renewable energy policy in the hands of the oil companies.” Producers like Archer Daniels Midland Co. (NYSE: ADM), Pacific Ethanol Inc. (NASDAQ: PEIX), and The Andersons Inc. (NASDAQ: ANDE) don’t have an oil refining business to offset the proposed cuts to ethanol volumes.

  • [By Tristan R. Brown]

    Three months ago I wrote that the stock performance YTD of independent ethanol producer Pacific Ethanol (PEIX) was an “aberration”, especially in light of the performance of its industry peers’ shares. The discrepancy between Pacific Ethanol’s share price and those of its peers has only grown more pronounced since July (see figure). Green Plains Renewable Energy (GPRE) and REX American Resources (REX) have continued to greatly outperform the S&P 500. Even Biofuel Energy, which fell behind on its interest and debt payments over the summer and is facing a shareholder-ruining liquidation, has seen its share price perform significantly better than Pacific Ethanol’s in 2013. The oddest part about the stock’s performance over the last three months, however, is that the period has been marked by multiple positive announcements from the company. It late July it reported its first positive EPS in almost two years for Q2 (0.07). Its Q2 EBITDA of $3.8 million was its highest sinc e Q4 2011. Its current ratio is well above its previous lows, its ratio of total assets to total liabilities is increasing, and its total shareholders’ equity is at a 3-year high. Despite these improvements, the company’s price/book ratio is a mere 0.77.

  • [By Paul Ausick]

    Ethanol producers like Pacific Ethanol Inc. (NASDAQ: PEIX), The Andersons Inc. (NASDAQ: ANDE) and Archer Daniels Midland Co. (NYSE: ADM), as well as other members of the trade group Renewable Fuels Association (RFA), are mightily displeased by this EPA proposal. Refiner and ethanol producer Valero Corp. (NYSE: VLO), which is not a member of the trade group, has been among the loudest critics of the higher blending requirements.

Top 5 Performing Stocks For 2014: TripAdvisor Inc (TRIP)

TripAdvisor, Inc. (TripAdvisor), incorporated on July 20, 2011, is an online travel research company, enabling users to plan and have a trip. TripAdvisor features reviews and advice on hotels, resorts, flights, vacation rentals, vacation packages and travel guides. TripAdvisor’s travel research platform features reviews and opinions from its community of travelers about destinations, accommodations (hotels, bed and breakfasts, specialty lodging and vacation rentals), restaurants and activities worldwide, through its TripAdvisor brand. TripAdvisor Websites include tripadvisor.com in the United States and versions of the Website in 30 countries, including in China under the brand daodao.com. TripAdvisor Websites also include links to the Websites of its travel advertisers allowing travelers to directly book their travel arrangements. In addition to the TripAdvisor brand, TripAdvisor, Inc. manages and operates Websites under 18 other travel media brands, providing travel pl anning resources across the travel sector. On December 20, 2011, Expedia, Inc. (Expedia) completed the spin-off of TripAdvisor, Inc. (TripAdvisor) to Expedia stockholders. TripAdvisor consists of the domestic and international operations previously associated with Expedia’s TripAdvisor Media Group. In October 2012, it acquired Wanderfly. In March 2013, it acquired Tiny Post (tinypost.co). In April 2013, the Company acquired Jetsetter.com and Gilt Travel Inc. In May 2013, TripAdvisor Inc acquired key technology and talent from CruiseWise Inc. In May 2013, TripAdvisor Inc acquired Guia de Apartamentos Niumba SL. In June 2013, the Company announced that it has acquired GateGuru.

TripAdvisor provides access worldwide to online travel agencies, including Expedia, Orbitz, Travelocity, hotels.com, Priceline and Booking.com. TripAdvisor Media Group offers travel suppliers graphical advertising and cost-per-click marketing platforms. TripAdvisor operates sites in 30 co untries and in 21 languages, including sites in the United S! tates (http://www.tripadvisor.com), the United Kingdom (http://www.tripadvisor.co.uk), France (http://www.tripadvisor.fr), Ireland (http://www.tripadvisor.ie), Germany (http://www.tripadvisor.de), Italy (http://www.tripadvisor.it), Spain (http://www.tripadvisor.es), India (http://www.tripadvisor.in), Japan (http://www.tripadvisor.jp), Portugal and Brazil (http://www.tripadvisor.com.br), Sweden (http://www.tripadvisor.se), The Netherlands (http://www.tripadvisor.nl), Canada (http://www.tripadvisor.ca), Denmark (http://www.tripadvisor.dk), Turkey (http://www.tripadvisor.com.tr), Mexico (http://www.tripadvisor.com.mx), Norway (http://no.tripadvisor.com), Poland (http://pl.tripadvisor.com), Australia (http://www.tripadvisor.com.au), Singapore (http://www.tripadvisor.com.sg), Thailand (http://th.tripadvisor.com), Russia (http://www.tripadvisor.ru), Greece (http://www.tripadvisor.com.gr), Indonesia(http://www.tripadvisor.co.id), Argentina (www.tripadvisor.co.ar), Taiwan (www.tripa dvisor.tw),Malaysia(http://www.tripadvisor.com.my), and Egypt (http://www.tripadvisor.com.eg). TripAdvisor also operates in China under the brand daodao.com (http://www.daodao.com) and Kuxun.cn (http://www.kuxun.cn).

Advisors’ Opinion:

  • [By John Udovich]

    Online review sites have become the first place many consumers turn to before making any type of purchase with online review stocks like Angie’s List Inc (NASDAQ: ANGI), OpenTable Inc (NASDAQ: OPEN), Yelp Inc (NYSE: YELP) and Tripadvisor Inc (NASDAQ: TRIP) being some of the publicly traded options for investors. But what is the best performing online review stock? First, here are the options to choose from:

  • [By Sue Chang and Saumya Vaishampayan]

    Expedia Inc. (EXPE)  shares skyrocketed 15%. The online travel agency reported fourth-quarter adjusted earnings of 92 cents a share, beating expectations. Its competitor TripAdvisor Inc. (TRIP)  climbed 10% and Priceline.com Inc. (PCLN)   added 4.8%.

  • [By Sue Chang and Saumya Vaishampayan]

    TripAdvisor Inc. (TRIP)  shares climbed 5.6%, recovering from moderate losses in the previous session. The stock has been volatile in recent days without a clear direction.

Top 5 Performing Stocks For 2014: AAON Inc.(AAON)

AAON, Inc., together with its subsidiaries, engages in the manufacture and sale of air conditioning and heating equipment primarily in the United States and Canada. The company offers rooftop units, chillers, air-handling units, make-up air units, heat recovery units, condensing units, commercial self contained units, and coils. It serves the commercial and industrial new construction and replacement markets. AAON, Inc. sells its products through manufacturers representatives and internal sales force. The company was founded in 1987 and is based in Tulsa, Oklahoma.

Advisors’ Opinion:

  • [By Jonas Elmerraji]

    We’re seeing the exact same setup in shares of small-cap HVAC firm Aaon (AAON). The biggest difference is that in AAON’s case, the ascending triangle pattern is coming in at the top of this stock’s recent price action, not at the bottom. That makes this a more textbook trade for September.

    Another important difference is the fact that AAON hasn’t triggered yet. Shares have been coiling below $26 resistance since the middle of the summer; a breakout above that $26 level is the indicator that it’s time to buy. Whenever you’re looking at any technical price pattern, it’s critical to think in terms of buyers and sellers. Triangles and other price pattern names are a good quick way to explain what’s going on in this stock, but they’re not the reason it’s tradable. Instead, it all comes down to supply and demand for shares.

    That resistance line at $26 is a price where there’s an excess of supply of shares; in other words, it’s a place where sellers have been more eager to take recent gains and sell their shares than buyers have been to buy. That’s what makes the move above it so significant — a breakout indicates that buyers are finally strong enough to absorb all of the excess supply above that price level.

    Wait for that to happen before you put your money on this trade.

Top 5 Performing Stocks For 2014: GenMark Diagnostics Inc.(GNMK)

GenMark Diagnostics, Inc. operates as a molecular diagnostics company primarily in the United States. It focuses on the development and commercialization of multiplexed molecular diagnostic testing systems for the detection and measurement of DNA and RNA targets used in the treatment of patients. The company?s products comprise eSensor XT-8 system, an automated molecular diagnostic system, which enable reference laboratories and hospitals to perform molecular diagnostic tests; and eSensor XT-8 Cartridge that utilizes a microfluidic system to accelerate target binding and enhance time to result. It also offers IVD tests, including eSensor cystic fibrosis genotyping test, eSensor thrombophilia risk test, and eSensor warfarin sensitivity test. The company?s other multiplexed molecular diagnostic tests pipeline under development comprise eSensor 2C19 test for the multiplexed detection and genotyping of various alleles of the cytochrome P450 (CYP450) 2C19 gene locus; eSensor re spiratory viral panel, a nucleic acid multiplex test for the simultaneous detection and identification of multiple respiratory virus nucleic acids and mutations that confer resistance of Influenza A to the anti-viral drug Oseltamivir (Tamiflu); and eSensor KRAS/BRAF test for the multiplexed detection and genotyping of 12 mutations in codons 12 and 13 of KRAS and the V600E mutation in BRAF. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.

Advisors’ Opinion:

  • [By Sean Williams]

    What: Shares of GenMark Diagnostics (NASDAQ: GNMK  ) , a molecular diagnostics company, slumped as much as 10% after updating its full-year revenue guidance after the bell last night.

  • [By Roberto Pedone]

    GenMark Diagnostics (GNMK) is a molecular diagnostics company, engages in the development, manufacturing, marketing, sale, and support of instruments and molecular tests based on its proprietary eSensor detection technology in the U.S. This stock closed up 1.7% to $9.89 in Tuesday’s trading session.

    Tuesday’s Range: $9.24-$9.95

    52-Week Range: $6.38-$16.00

    Thursday’s Volume: 562,000

    Three-Month Average Volume: 385,008

    From a technical perspective, GNMK bounced modestly higher here with above-average volume. This stock has been trending sideways inside of a consolidation chart pattern for the last two months, with shares moving between $8.75 on the downside and $10.71 on the upside. This bounce is starting to push GNMK within range of triggering a near-term breakout trade above the upper-end of its sideways trading chart pattern. That breakout will hit if GNMK manages to clear some near-term overhead resistance levels at $10.04 to $10.50 and then once it takes out more resistance at $10.71 with high volume.

    Traders should now look for long-biased trades in GNMK as long as it’s trending above Tuesday’s low of $9.24 or around $9 and then once it sustains a move or close above those breakout levels with volume that hits near or above 385,008 shares. If that breakout triggers soon, then GNMK will set up to re-test or possibly take out its next major overhead resistance levels at $12 to $13.50.

Top 5 Performing Stocks For 2014: Regeneron Pharmaceuticals Inc.(REGN)

Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes pharmaceutical products for the treatment of serious medical conditions in the United States. The company?s commercial product includes ARCALYST (rilonacept) injection for subcutaneous use for the treatment of cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome in adults and children. Its products under Phase III clinical development stage consist of VEGF Trap-Eye, an aflibercept ophthalmic solution developed using intraocular delivery for the treatment of serious eye diseases; ARCALYST for the prevention of gout flares in patients initiating uric acid-lowering treatment; and Aflibercept (VEGF Trap), which is developed in oncology. The company?s earlier stage clinical programs include various human antibodies, such as REGN727 for low-density lipoprotein cholesterol reduction, REGN88 for rheumatoid arthritis and ankylosing spondylitis; REGN668 for atopic dermatitis and asthma; REGN421 and REGN910 for oncology; REGN475 for the treatment of pain; and REGN728 and REGN846. It also conducts preclinical research programs in the areas of oncology and angiogenesis, ophthalmology, metabolic and related diseases, muscle diseases and disorders, inflammation and immune diseases, bone and cartilage, pain, cardiovascular diseases, and infectious diseases. The company distributes its products through third party service providers. It has strategic collaboration with sanofi-aventis Group to discover, develop, and commercialize human monoclonal antibodies; and Bayer HealthCare LLC to develop and commercialize VEGF Trap. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is based in Tarrytown, New York.

Advisors’ Opinion:

  • [By Ben Levisohn]

    Shares of Regeneron Pharmaceuticals (REGN) have fallen 4.4% to $323.62 at 3:23 p.m., while Biogen (BIIB) has dropped 4% to $327.04 and Gilead Sciences (GILD) has dipped 0.4% to $79.58. The iShares Nasdaq Biotechnology Index ETF (IBB), meanwhile, has dropped 0.9% to $258.85 and the SPDR S&P Biotech ETF (XBI) has declined 0.6% to $160.69. Suffice it to say, biotech investors don’t appear to be enjoying zero-G nearly as much as Kate Upton.

  • [By Ben Levisohn]

    Whatever the reason, the day was clearly a painful one for biotech investors, who have already been facing charges of bubble-mania in the sector. The SPDR S&P Biotech ETF (XBI) fell 3.1%, the iShares Nasdaq Biotechnology Index ETF (IBB) dropped 2.7%, while Amgen (AMGN) fell 1.6% and Regeneron Pharmaceuticals (REGN) declined 2%.

  • [By Ben Levisohn]

    Earlier today, the S&P 500 looked like it would close at an all-time high. Then the bears roared, and S&P 500 gave back about half its gains despite big moves in United Health (UNH), Humana (HUM), Pioneer Natural Resources (PXD), ExxonMobil (XOM) and  Regeneron (REGN).

  • [By Ben Levisohn]

    Investors are eying big gains in Regeneron Pharmaceuticals (REGN) following its earnings release today, which featured good news on the biotech company’s blockbuster-to-be, Eylea.

    Getty Images

    Reuters has the details on Regeneron’s results:

    Regeneron Pharmaceuticals Inc forecast U.S. sales of eye drug Eylea to reach $1.7-$1.8 billion in 2014 as it expects the drug to win approval for newer uses, sending its shares up 3 percent before the opening bell.

    Regeneron, whose stock has been propelled by the success of Eylea, said U.S. sales of the sight-saving drug rose 46 percent to $402 million in the fourth quarter. The drug’s international sales touched $184 million in the quarter…

    The company’s net income fell to $97 million, or 86 cents per share, in the quarter ended December 31, from $470 million, or $4.08 per share, a year earlier. The year-ago quarter included a non-cash tax benefit of $336 million.

    Analysts had expected a profit of 98 cents per share, according to Thomson Reuters I/B/E/S.

    RBC Capital Market’s Adnan Butt and team note that Eylea sales could be better than management forecasts:

    The trend shows growth over 4Q run-rate and is deemed a positive as management is typically viewed as conservative when it comes to guidance. Questions on the call will focus on what is included, i.e., whether it includes DME or not which is not yet approved. We like [Regeneron] for the blockbuster potential of Eylea and the deep pipeline and are buyers, especially on any pullbacks. It is one of our top ideas for 2014.

    Brean Capital’s Jonathan Aschoff and Yi Cheng raise their target price on Regeneron to $380 from $367. They explain why:

    4Q13, U.S. Eylea sales were hurt by the holiday season but helped by an increase in inventory held by distributors to over two weeks, which should negatively affect sequential Eylea sales in 1Q14. In 4Q13, Eylea had 50% of the U.S